Latest news with #BlackDiamondTherapeutics
Yahoo
20-05-2025
- Business
- Yahoo
3 Promising Penny Stocks With Market Caps Under $200M
The U.S. stock market has experienced a slight downturn, following a period of gains for the S&P 500, as investors digest recent economic developments and corporate earnings. In this context, penny stocks continue to capture attention as they represent smaller or newer companies that can offer unique investment opportunities. While the term might seem outdated, these stocks still hold potential for growth when backed by strong financials and solid fundamentals. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.71 $393.17M ★★★★☆☆ Tuya (NYSE:TUYA) $2.64 $1.64B ★★★★★★ Perfect (NYSE:PERF) $1.78 $181.29M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.25 $55.65M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.50 $86.38M ★★★★★★ Table Trac (OTCPK:TBTC) $4.50 $21.82M ★★★★★★ BAB (OTCPK:BABB) $0.8495 $5.75M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.14 $73.52M ★★★★★☆ New Horizon Aircraft (NasdaqCM:HOVR) $0.69 $21.41M ★★★★★★ CBAK Energy Technology (NasdaqCM:CBAT) $0.805 $78.43M ★★★★★☆ Click here to see the full list of 720 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Black Diamond Therapeutics, Inc. is a clinical-stage oncology company dedicated to discovering and developing MasterKey therapies for genetically defined tumors, with a market cap of $110.88 million. Operations: Black Diamond Therapeutics, Inc. currently does not report any revenue segments. Market Cap: $110.88M Black Diamond Therapeutics has recently transitioned to profitability, reporting a net income of US$56.54 million for Q1 2025, a significant improvement from the previous year's loss. The company is debt-free with strong short-term assets of US$155.7 million exceeding liabilities and has secured a strategic licensing agreement with Servier for BDTX-4933, potentially yielding up to US$710 million in milestone payments. Despite its low return on equity at 3.6%, analysts expect substantial stock price growth, though earnings are forecasted to decline by 33.1% annually over the next three years due to its pre-revenue status in oncology therapies development. Dive into the specifics of Black Diamond Therapeutics here with our thorough balance sheet health report. Gain insights into Black Diamond Therapeutics' outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for hematologic malignancies and autoimmune diseases, with a market cap of $87.28 million. Operations: Caribou Biosciences generates revenue primarily from developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies, amounting to $9.92 million. Market Cap: $87.28M Caribou Biosciences, Inc. remains unprofitable with a net loss of US$39.99 million in Q1 2025, though losses have slightly narrowed compared to the previous year. The company is debt-free and holds strong short-term assets of US$217.3 million, exceeding its liabilities significantly. Recent strategic moves include a proposed reverse stock split and pipeline prioritization to extend its cash runway into late 2027. Despite high volatility and ongoing equity offerings totaling up to US$400 million, revenue is forecasted to grow substantially at over 70% annually as it advances its clinical-stage therapies for hematologic malignancies and autoimmune diseases. Click to explore a detailed breakdown of our findings in Caribou Biosciences' financial health report. Understand Caribou Biosciences' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to developing and commercializing cancer care products both in the United States and internationally, with a market cap of approximately $168.27 million. Operations: The company generates $232.71 million in revenue from the development and commercialization of innovative cancer care products. Market Cap: $168.27M Puma Biotechnology, Inc. has demonstrated significant earnings growth, with a 147.6% increase over the past year and profitability achieved over the last five years. The company's financial health is supported by more cash than debt and a strong balance sheet where short-term assets exceed liabilities. Recent revenue figures indicate steady performance, with US$46.01 million reported in Q1 2025 compared to US$43.8 million a year ago, alongside net income of US$2.97 million reversing prior losses. Strategic partnerships for NERLYNX® expansion into Eastern Europe and Central Asia could further bolster its market presence in oncology treatments. Jump into the full analysis health report here for a deeper understanding of Puma Biotechnology. Examine Puma Biotechnology's earnings growth report to understand how analysts expect it to perform. Access the full spectrum of 720 US Penny Stocks by clicking on this link. Interested In Other Possibilities? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:BDTX NasdaqGS:CRBU and NasdaqGS:PBYI. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Business Insider
13-05-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Black Diamond Therapeutics (BDTX)
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The company's shares closed today at $1.75. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Kymera Therapeutics, and Janux Therapeutics Inc. According to TipRanks, Frahm has an average return of -0.3% and a 33.56% success rate on recommended stocks. Currently, the analyst consensus on Black Diamond Therapeutics is a Strong Buy with an average price target of $13.50. The company has a one-year high of $6.75 and a one-year low of $1.20. Currently, Black Diamond Therapeutics has an average volume of 3.32M. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDTX in relation to earlier this year. Most recently, in March 2025, BIOTECH GROWTH N V, a Major Shareholder at BDTX sold 5,784,292.00 shares for a total of $11,972,369.40.
Yahoo
19-03-2025
- Business
- Yahoo
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancer Black Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors. 'At Servier, we are dedicated to transforming patient care in areas with significant unmet needs. Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time,' said Claude Bertrand, Executive Vice-President of R&D at Servier. 'We look forward to accelerating the development of this therapy as a potential best-in-class treatment for cancer patients.' 'This agreement supports our mission to advance oral cancer therapies designed to give patients the opportunity for longer, healthier, and more active lives,' said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. 'Servier's commitment to innovation and deep expertise in oncology make it an ideal partner for Black Diamond as we work to develop breakthrough cancer treatments.' Under the terms of the agreement, Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications, including non-small cell lung cancer (NSCLC), with potential applications in other solid tumors. Black Diamond Therapeutics will receive an upfront payment of $70 million and will be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales. Currently in Phase 1 development, BDTX-4933 is uniquely designed to target RAS and RAF alterations in solid tumors. The dose escalation and expansion cohort first-in-human study aims at evaluating safety and tolerability, the preliminary recommended Phase 2 dose, and antitumor activity of BDTX-4933 in adults with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations. Servier Contact For Media: presse@ Black Diamond Therapeutics ContactsFor Investors: investors@ For Media: media@ About Servier Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group's unique governance model preserves its independence while prioritizing long-term innovation for patients by reinvesting 100% of its profit in development of the company. As a world leader in cardiometabolism and venous diseases, Servier brings transformative innovation in chronic diseases thanks to its holistic approach, making patient adherence a global priority. With the ambition of becoming a leading player in the field of rare cancers, Servier deeply invest in oncology and devotes close to 70% of its R&D budget to this field using precision medicine to create more effective treatments. Building on the Group's success in oncology, Servier has decided to invest in neurology, a future growth driver for the Group. As such, Servier is focusing on a limited number of neurodegenerative diseases where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe, and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier medicines are available in close to 140 countries. In 2023/2024, the Group which employs over 22,000 people worldwide, achieved sales revenue of €5.9 billion. More information on: Follow us on social media: LinkedIn, Facebook, Twitter, Instagram About Black Diamond Therapeutics Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the partnership with Servier and the intended and potential benefits thereof, including the receipt of potential milestone and royalty payments from commercial product sales, along with tiered royalties based on global net sales, if any; Servier's ability to develop and commercialize BDTX-4933, including the ongoing Phase 1 clinical trial of BDTX-4933; and the potential of BDTX-4933 to address the unmet medical need for patients with RAF/RAS-mutant solid tumors, including NSCLC. Any forward-looking statements in this press release are based on Black Diamond's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Black Diamond's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the United States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Black Diamond undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were in to access your portfolio
